Category: Blog
-
Reshaping the Future of Clinical Trials
[vc_row][vc_column][vc_column_text css=”.vc_custom_1555864690658{margin-bottom: 0px !important;}”]The traditional method for evaluating clinical trial data in phase 2 and phase 3 studies requires sponsors to collect enough data to support an Independent Data Monitoring Committee (IDMC) review. Over half of these results are negative, causing sponsors to waste valuable time and millions in lengthy clinical trials. The FDA has…